APA (7th ed.) Citation

Hu, G., Zhu, W., Liu, Y., Wang, Y., Zhang, Z., Zhu, S., . . . Huo, L. (2022). Development and comparison of three 89Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: A preclinical study. European Journal of Nuclear Medicine & Molecular Imaging, 49(8), 2634. https://doi.org/10.1007/s00259-022-05739-3

Chicago Style (17th ed.) Citation

Hu, Guilan, et al. "Development and Comparison of Three 89Zr-labeled Anti-CLDN18.2 Antibodies to Noninvasively Evaluate CLDN18.2 Expression in Gastric Cancer: A Preclinical Study." European Journal of Nuclear Medicine & Molecular Imaging 49, no. 8 (2022): 2634. https://doi.org/10.1007/s00259-022-05739-3.

MLA (9th ed.) Citation

Hu, Guilan, et al. "Development and Comparison of Three 89Zr-labeled Anti-CLDN18.2 Antibodies to Noninvasively Evaluate CLDN18.2 Expression in Gastric Cancer: A Preclinical Study." European Journal of Nuclear Medicine & Molecular Imaging, vol. 49, no. 8, 2022, p. 2634, https://doi.org/10.1007/s00259-022-05739-3.